KR20120050442A - 플라스미노겐 및 플라스민의 변이체 - Google Patents

플라스미노겐 및 플라스민의 변이체 Download PDF

Info

Publication number
KR20120050442A
KR20120050442A KR1020127003121A KR20127003121A KR20120050442A KR 20120050442 A KR20120050442 A KR 20120050442A KR 1020127003121 A KR1020127003121 A KR 1020127003121A KR 20127003121 A KR20127003121 A KR 20127003121A KR 20120050442 A KR20120050442 A KR 20120050442A
Authority
KR
South Korea
Prior art keywords
pro
plasmin
gly
glu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127003121A
Other languages
English (en)
Korean (ko)
Inventor
리하르트 레이니어 즈발
Original Assignee
쓰롬보제닉스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쓰롬보제닉스 엔.브이. filed Critical 쓰롬보제닉스 엔.브이.
Publication of KR20120050442A publication Critical patent/KR20120050442A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/484Plasmin (3.4.21.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6435Plasmin (3.4.21.7), i.e. fibrinolysin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21007Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020127003121A 2009-07-10 2010-07-09 플라스미노겐 및 플라스민의 변이체 Ceased KR20120050442A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22451409P 2009-07-10 2009-07-10
EP09165237.0 2009-07-10
US61/224,514 2009-07-10
EP09165237 2009-07-10

Publications (1)

Publication Number Publication Date
KR20120050442A true KR20120050442A (ko) 2012-05-18

Family

ID=40972886

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127003121A Ceased KR20120050442A (ko) 2009-07-10 2010-07-09 플라스미노겐 및 플라스민의 변이체

Country Status (13)

Country Link
US (1) US9226953B2 (enExample)
EP (1) EP2451835A1 (enExample)
JP (1) JP5819293B2 (enExample)
KR (1) KR20120050442A (enExample)
CN (1) CN102482338B (enExample)
AU (1) AU2010270146B9 (enExample)
CA (1) CA2767612A1 (enExample)
IL (1) IL217113A0 (enExample)
MX (1) MX2012000475A (enExample)
NZ (1) NZ597452A (enExample)
RU (1) RU2564131C2 (enExample)
WO (1) WO2011004011A1 (enExample)
ZA (1) ZA201200191B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170010798A (ko) * 2014-05-28 2017-02-01 파피에르패브릭 어거스트 쾰러 에스이 감열성 기록물질

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
PL2785739T3 (pl) * 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
JP6483083B2 (ja) * 2013-03-14 2019-03-13 ウェイン ステイト ユニバーシティー 治療用化合物の眼への送達を増強する方法
EP2821081A1 (en) 2013-07-05 2015-01-07 ResuSciTec GmbH Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
HUE068351T2 (hu) * 2014-12-19 2024-12-28 Kedrion Biopharma Inc Plazminogént tartalmazó gyógyszerkészítmény és annak felhasználásai
RU2597782C1 (ru) * 2015-08-25 2016-09-20 Василий Николаевич Яковлев Способ определения содержания продуктов протеолиза в плазме крови и диагностическая тест-система для его осуществления
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
JP6815413B2 (ja) * 2015-12-18 2021-01-20 タレンゲン インターナショナル リミテッドTalengen International Limited 肝組織損傷及びその関連疾患を予防及び治療するための方法
JP6876066B2 (ja) 2015-12-18 2021-05-26 タレンゲン インターナショナル リミテッドTalengen International Limited 子宮膣部びらんを予防及び治療するための方法
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN106890320A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
EP3391902B1 (en) 2015-12-18 2023-10-18 Talengen International Limited Plasminogen for use in the treatment of diabetic angiocardiopathy
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
CN108210905A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗皮肤纤维化的药物及其用途
TW201822809A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療高脂血症的方法
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TWI763680B (zh) 2016-12-15 2022-05-11 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備藥物中的用途
CN108210898A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪异常沉积导致的组织损伤的药物及其用途
CN108210917A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
WO2018108161A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556380A4 (en) * 2016-12-15 2020-05-13 Talengen International Limited METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN
ES3036897T3 (en) 2017-06-19 2025-09-25 Talengen Int Ltd Plasminogen for use in treating parkinson's and alzheimer's disease
CN113795274A (zh) * 2019-05-10 2021-12-14 泰伦基国际有限公司 一种治疗肌萎缩侧索硬化的方法和药物
TW202143999A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
CN113755476B (zh) * 2021-10-14 2023-04-11 北京农学院 蛆激酶制备方法及其用途
CN119331857B (zh) * 2024-12-19 2025-05-16 南通大学 一种新型重组蛋白Plasminogen-CTM及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208908A (en) 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US4122158A (en) 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
NZ191320A (en) 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
FI915149A7 (fi) 1989-05-01 1991-10-31 The Univ Of Notre Dame Du Lac Menetelmiä ja aineksia ihmisen plasminogeenin ilmentämiseksi eukaryoot tisolujärjestelmässä, josta puuttuu kohdepesifinen plasminogeeniaktiva attori
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US5288489A (en) 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
AU6138396A (en) 1995-06-26 1997-01-30 Daiichi Pure Chemicals Co., Ltd. Stable plasmin solution
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
EP0910571B1 (en) * 1996-05-03 2005-07-20 Abbott Laboratories Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
JP4577992B2 (ja) * 1998-09-29 2010-11-10 リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー 虚血性卒中の処置用の組成物を調製するための、α2抗プラスミンをインビボで減少する化合物の使用
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
AU781638B2 (en) 1999-07-14 2005-06-02 D. Collen Research Foudation Vzw Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
EP1263452A4 (en) * 2000-02-08 2006-12-20 Univ Northwestern METHODS AND COMPOSITIONS FOR PRODUCING ANGIOSTATIN
EP1343903B1 (en) 2000-12-21 2007-11-14 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
US20020139378A1 (en) 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
MXPA04007585A (es) 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20040235115A1 (en) 2002-11-18 2004-11-25 Reed Guy L. Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
ES2412489T3 (es) 2003-08-14 2013-07-11 Thrombogenics N.V. Anticuerpos contra el factor VIII con glucosilación modificada en la región variable
US7659445B2 (en) 2004-02-11 2010-02-09 Biolex Therapeutics, Inc. Expression of plasminogen and microplasminogen in duck weed
CN1253560C (zh) 2004-03-01 2006-04-26 宁夏大学 组织型纤溶酶原激活剂缺失/点突变体基因转染细胞株
ES2349555T3 (es) 2004-04-22 2011-01-05 Talecris Biotherapeutics, Inc. Plasmina modificada recombinántemente.
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007047874A2 (en) 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134231A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070134230A1 (en) 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
CN101573134B (zh) 2006-08-28 2013-03-06 李季男 抗感染候选药物
CN101730740A (zh) 2006-09-29 2010-06-09 蛋白质组技术公司 用于生产重组纤溶酶原和纤溶酶多肽的方法
MX2010005947A (es) 2007-11-29 2010-09-10 Talecris Biotherapeutics Inc Plasmina modificada de forma recombinante.
WO2009073457A1 (en) 2007-11-30 2009-06-11 Bausch & Lomb Incorporated Methods and compositions for the rescue of a filtering bleb
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170010798A (ko) * 2014-05-28 2017-02-01 파피에르패브릭 어거스트 쾰러 에스이 감열성 기록물질

Also Published As

Publication number Publication date
CN102482338A (zh) 2012-05-30
HK1167265A1 (zh) 2012-11-23
CA2767612A1 (en) 2011-01-13
JP2012532596A (ja) 2012-12-20
US20120114630A1 (en) 2012-05-10
US9226953B2 (en) 2016-01-05
IL217113A0 (en) 2012-02-29
CN102482338B (zh) 2016-09-28
AU2010270146B9 (en) 2015-04-02
RU2012103949A (ru) 2013-08-20
AU2010270146B2 (en) 2015-02-05
ZA201200191B (en) 2012-09-26
NZ597452A (en) 2013-10-25
EP2451835A1 (en) 2012-05-16
AU2010270146A1 (en) 2012-02-02
RU2564131C2 (ru) 2015-09-27
JP5819293B2 (ja) 2015-11-24
MX2012000475A (es) 2012-03-26
WO2011004011A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
RU2564131C2 (ru) Варианты плазминогена и плазмина
EP2661493B1 (en) Plasminogen and plasmin variants
JP6000353B2 (ja) プラスミノーゲンおよびプラスミンの変異体
HK1193747A (en) Plasminogen and plasmin variants
NZ612836B2 (en) Plasminogen and plasmin variants
HK1167265B (en) Variants of plasminogen and plasmin
NZ622210B2 (en) Plasminogen and plasmin variants
HK1191054A (en) Plasminogen and plasmin variants
HK1191054B (en) Plasminogen and plasmin variants

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150709

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160330

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161021

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170425

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20171031

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20161021

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20160330

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I